SOLICITATION NOTICE
A -- PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing - Statement of Work- PREVENT Toxicology and Pharmacology Testing
- Notice Date
- 11/27/2017
- Notice Type
- Presolicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N0CN45009
- Archive Date
- 12/27/2017
- Point of Contact
- Kelly L Dempsey, Phone: 3018466654, Nicole Belanger, Phone: 301 624 8754
- E-Mail Address
-
kelly.dempsey@nih.gov, belangern@mail.nih.gov
(kelly.dempsey@nih.gov, belangern@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Statement of Work- PREVENT Pharmacology/Toxicology Testing Notice of Intent to Sole Source PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing This is a sole source synopsis for the I ndefinite Delivery Indefinite Quantity (IDIQ) contracts within the PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing. This announcement constitutes the only synopsis for this requirement, is issued for notification purposes only and is not a request for competitive proposals. The National Cancer Institute (NCI) plans to issue modifications to increase the ceilings on each contract in the IDIQ Toxicology pool to provide continued support in the conduct of toxicological and pharmacological evaluations of potential cancer preventive agents for Investigational New Drug applications to the Food and Drug Administration (FDA) for phase 0, 1-3 clinical studies. This work is accomplished through studies in genotoxicity testing, general toxicology in experimental animals, reproductive toxicology studies in rodents and rabbits and other specialized studies. The modifications for this requirement are anticipated to take place on or about September 30, 2017. The five contractors currently within the Toxicology IDIQ pool are as follows: HHSN261201500021I, SRI International, 333 Ravenswood Ave., Menlo Park, CA 94025 HHSN261201500022I, Southern Research Institute, 2000 9th Ave. S., Birmingham, AL 35205 HHSN261201500023I, Lovelace Biomedical & Environmental Research Institute, 2425 Ridgecrest Dr. SE, Albuquerque, NM 87108 HHSN261201500024I, IIT Research Institute, 10 W. 35th Street, Chicago, IL 60616 HHSN261201500026I, University of Illinois at Chicago, 506 S. Wright St. 364 Henry Admin Bldg, Urbana, IL 61801 These modifications will increase the ceiling value on the Base IDIQ contracts from $9 million by $10 million to $19 million. In order to ensure operation and continuity of essential research and development services during the next two cycles of the PREVENT Program, NCI needs to increase the ceiling, which will allow for the funding of complex task orders that include immunoprevention projects associated with specialized, expensive assays and procedures, among other projects. The NCI intends to issue these modifications on a non-competitive basis to each of the five contractors in the Tox IDIQ pool in accordance with 10 U.S.C 2304(c)(1), as implemented by FAR 6.302-1(a)(2), "Only one responsible source and no other supplies or services will satisfy agency requirements." This notice is not a request for competitive proposals; however, if any interested and responsible source, especially small businesses, believes it can meet the requirements, submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Interested organizations may submit their capabilities and qualifications to perform the effort in writing to the identified point of contact not later than 3:30 p.m., Eastern Standard Time, on August 29, 2017. Such capabilities/qualifications will be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Oral and facsimile communications shall not be accepted in response to this notice. In accordance with FAR 16.505(b)(8), the following individual has been designated as the NIH Ombudsman for these task order contracts: Dr. Sherry Mills NIH Competitio n Advocate for R&D Contracts 6705 Rockledge Drive, Suite 305 Bethesda, MD 20892 Phone: 301-435-2729 E-mail: sherry.mills@nih.gov DISCLAIMER: THIS NOTICE IS FOR INFORMATIONAL AND PLANNING PURPOSES ONLY. THIS IS NOT A REQUEST FOR QUOTE AND IS NOT A COMMITMENT BY THE US GOVERNMENT TO PROCURE SUBJECT PRODUCTS. NO SOLICITATION SHALL RESULT FROM THIS NOTICE. NO FUNDS ARE AVAILABLE TO ACCOUNT FOR PREPARATION OF RESPONSES TO THIS NOTIFICATION. THE GOVERNMENT WILL USE THE INFORMATION RECEIVED TO DETERMINE WHETHER OTHER SOURCES ARE AVAILABLE THAT ARE CAPABLE TO SATISFY THIS REQUIREMENT.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N0CN45009/listing.html)
- Place of Performance
- Address: Contractor's Facilities, United States
- Record
- SN04749271-W 20171129/171127230942-7e373701a96a81d542d5fcf3d3b3a460 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |